Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Spain Policy

How England Is Undermining Clinical Research

This article was originally published in Scrip

Executive Summary

Authorities in England are viewing life-extending medicines as "simple commodities like groceries", says Wim Souverijns, general manager of Celgene UK & Ireland. Without a change in attitude, and if plans for a new Cancer Drugs Fund go ahead, companies could decide to relocate their studies from England, although plans for devolution could provide a chink of light for companies, says Souverijns.

Table

View full table

Topics

Tags:
Cancer Spain Policy
Latest Headlines

Pipeline Watch: Eighteen Approvals And Six Phase III Trial Updates

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

See All
UsernamePublicRestriction

Register

SC064561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By